In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...
Read MoreType(s) of hormonal therapy-Luteinizing hormone-releasing hormone (LHRH) antagonists Posts on Medivizor
Hormone therapy and its impact on cognitive performance
In a nutshell The authors aimed to determine the changes in cognitive performance (CP) after 6 months of hormone therapy with luteinizing hormone-releasing hormone (LHRH) analogues. The authors concluded that CP in men with prostate cancer does not appear to be affected following 6 months of LHRH treatment. Some background Androgen...
Read More